AbbVie Inc (BUE:ABBV)
ARS 21100 275 (1.32%) Market Cap: 326.28 Til Enterprise Value: 391.76 Til PE Ratio: 63.33 PB Ratio: 53.42 GF Score: 74/100

Abbvie Inc at Wolfe Research Healthcare Conference Transcript

Nov 15, 2022 / 04:30PM GMT
Release Date Price: ARS4040.5
Timothy Minton Anderson
Wolfe Research, LLC - MD of Equity Research

Same on Friday and on Wednesday and Thursday this week, we'll have the live conference itself and a smattering of companies from my coverage as well as Justin Lake and Mike Buller. So we're happy right now to have AbbVie with us. Various members of the management team, including Rob Michael, and Jeff Stewart and Scott Reents and Neil Gallagher as well as Liz Shea from Investor Relations, and it's going to be a fireside chat discussion. And with that, we're going to go ahead and just jump right in. We've got a lot of content to cover.

So welcome, everyone. Maybe high-level questions first. We'll get to Humira that will be a source of many questions. But outside of Humira, can you just talk about the pushes and pulls that you see in 2023 unrelated to Humira.

Robert A. Michael
AbbVie Inc. - Vice Chairman & President

Sure. Thanks. It's very nice to be with you today. I'd say outside of Humira, obviously, we'll talk about quite a bit. I mean, clearly, in terms of pushes and pulls, I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot